Zimmer Partners LP Acquires 166,500 Shares of Evolus, Inc. (NASDAQ:EOLS)

Zimmer Partners LP boosted its holdings in Evolus, Inc. (NASDAQ:EOLS - Free Report) by 66.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 416,500 shares of the company's stock after purchasing an additional 166,500 shares during the period. Zimmer Partners LP owned about 0.66% of Evolus worth $4,598,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. KBC Group NV purchased a new position in shares of Evolus during the 4th quarter valued at $49,000. IFP Advisors Inc lifted its position in shares of Evolus by 17,440.7% during the 4th quarter. IFP Advisors Inc now owns 4,736 shares of the company's stock valued at $52,000 after buying an additional 4,709 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new position in shares of Evolus during the 4th quarter valued at $106,000. Rafferty Asset Management LLC purchased a new position in shares of Evolus during the 4th quarter valued at $115,000. Finally, Quantbot Technologies LP purchased a new position in shares of Evolus during the 4th quarter valued at $118,000. Hedge funds and other institutional investors own 90.69% of the company's stock.

Analysts Set New Price Targets

A number of analysts recently issued reports on EOLS shares. HC Wainwright reissued a "buy" rating and set a $27.00 price objective on shares of Evolus in a report on Thursday, April 10th. Barclays increased their price objective on Evolus from $22.00 to $25.00 and gave the stock an "overweight" rating in a report on Wednesday, March 5th. Needham & Company LLC reissued a "buy" rating and set a $22.00 price objective on shares of Evolus in a report on Thursday, May 8th. Finally, BTIG Research started coverage on Evolus in a report on Thursday, April 17th. They set a "buy" rating and a $21.00 price objective on the stock. Five analysts have rated the stock with a buy rating, According to MarketBeat, Evolus currently has a consensus rating of "Buy" and a consensus target price of $23.75.

Insider Activity at Evolus

In other news, CFO Sandra Beaver sold 8,996 shares of Evolus stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $13.26, for a total value of $119,286.96. Following the sale, the chief financial officer now directly owns 173,583 shares in the company, valued at approximately $2,301,710.58. This trade represents a 4.93% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Karah Herdman Parschauer sold 12,888 shares of Evolus stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $12.99, for a total value of $167,415.12. Following the completion of the sale, the director now owns 32,183 shares in the company, valued at approximately $418,057.17. This represents a 28.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 86,241 shares of company stock worth $1,048,666 in the last ninety days. 5.90% of the stock is owned by company insiders.

Evolus Price Performance

Shares of Evolus stock traded up $0.12 during trading on Friday, hitting $9.68. 462,704 shares of the stock traded hands, compared to its average volume of 694,791. The company has a quick ratio of 2.23, a current ratio of 2.47 and a debt-to-equity ratio of 20.58. The stock has a market cap of $624.13 million, a price-to-earnings ratio of -10.64 and a beta of 1.11. The firm's fifty day moving average is $10.97 and its 200-day moving average is $12.10. Evolus, Inc. has a 52 week low of $8.67 and a 52 week high of $17.82.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.